Cited 2 times in
First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 장지석 | - |
dc.contributor.author | 김경환 | - |
dc.contributor.author | 신상준 | - |
dc.contributor.author | 금웅섭 | - |
dc.contributor.author | 정기양 | - |
dc.contributor.author | 노미령 | - |
dc.contributor.author | 김상겸 | - |
dc.contributor.author | 정민규 | - |
dc.contributor.author | 김규현 | - |
dc.date.accessioned | 2022-12-22T05:10:43Z | - |
dc.date.available | 2022-12-22T05:10:43Z | - |
dc.date.issued | 2022-11 | - |
dc.identifier.issn | 0190-9622 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/192325 | - |
dc.description.abstract | Background: Limited data are available to assist the selection between immune checkpoint inhibitors and BRAF/mitogen-activated protein kinase kinase inhibitors as first-line treatment for patients with BRAF-mutant advanced malignant melanoma. Objective: To investigate the outcomes associated with first-line pembrolizumab or dabrafenib/trametinib treatment for advanced melanoma with activating BRAF V600 mutation. Methods: Data of patients with BRAF V600-mutant melanoma who were treated with first-line pembrolizumab (n = 40) or dabrafenib/trametinib (n = 32) were analyzed. Tumor response, progression-free survival, and overall survival were evaluated. Immune evasion accompanied with emerging resistance to BRAF/mitogen-activated protein kinase kinase inhibitors was assessed. Results: A longer overall survival was observed after first-line pembrolizumab treatment than after first-line dabrafenib/trametinib treatment (hazard ratio = 2.910, 95% CI: 1.552-5.459), although there were no significant differences in progression-free survival (P = .375) and response rate (P = .123). Emergence of resistance to dabrafenib/trametinib co-occurred with immune evasion, enabling melanoma cells to escape recognition and killing by Melan-A-specific CD8+ T cells. Limitations: Analysis was conducted in a retrospective manner. Conclusion: Pembrolizumab may be recommended over BRAF/mitogen-activated protein kinase kinase inhibitors as the first-line treatment in patients with advanced BRAF V600-mutant melanoma. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Mosby | - |
dc.relation.isPartOf | JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / therapeutic use | - |
dc.subject.MESH | CD8-Positive T-Lymphocytes / pathology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Imidazoles | - |
dc.subject.MESH | Immune Checkpoint Inhibitors | - |
dc.subject.MESH | MART-1 Antigen | - |
dc.subject.MESH | Melanoma* / drug therapy | - |
dc.subject.MESH | Melanoma* / genetics | - |
dc.subject.MESH | Melanoma* / pathology | - |
dc.subject.MESH | Mitogen-Activated Protein Kinase Kinases | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Oximes / therapeutic use | - |
dc.subject.MESH | Protein Kinase Inhibitors / therapeutic use | - |
dc.subject.MESH | Proto-Oncogene Proteins B-raf / genetics | - |
dc.subject.MESH | Pyridones / adverse effects | - |
dc.subject.MESH | Pyrimidinones | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Skin Neoplasms* / drug therapy | - |
dc.subject.MESH | Skin Neoplasms* / genetics | - |
dc.subject.MESH | Skin Neoplasms* / pathology | - |
dc.title | First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학교실) | - |
dc.contributor.googleauthor | Chang Gon Kim | - |
dc.contributor.googleauthor | Miso Kim | - |
dc.contributor.googleauthor | Jieon Hwang | - |
dc.contributor.googleauthor | Seung Tae Kim | - |
dc.contributor.googleauthor | Minkyu Jung | - |
dc.contributor.googleauthor | Kyoo Hyun Kim | - |
dc.contributor.googleauthor | Kyung Hwan Kim | - |
dc.contributor.googleauthor | Jee Suk Chang | - |
dc.contributor.googleauthor | Woong Sub Koom | - |
dc.contributor.googleauthor | Mi Ryung Roh | - |
dc.contributor.googleauthor | Kee Yang Chung | - |
dc.contributor.googleauthor | Tae Min Kim | - |
dc.contributor.googleauthor | Sang Kyum Kim | - |
dc.contributor.googleauthor | Jeeyun Lee | - |
dc.contributor.googleauthor | Sang Joon Shin | - |
dc.identifier.doi | 10.1016/j.jaad.2022.07.057 | - |
dc.contributor.localId | A04658 | - |
dc.contributor.localId | A05226 | - |
dc.contributor.localId | A02105 | - |
dc.contributor.localId | A00273 | - |
dc.contributor.localId | A03582 | - |
dc.contributor.localId | A01278 | - |
dc.contributor.localId | A00520 | - |
dc.relation.journalcode | J01766 | - |
dc.identifier.eissn | 1097-6787 | - |
dc.identifier.pmid | 36068115 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0190962222024434?via%3Dihub | - |
dc.subject.keyword | BRAF V600–mutant advanced melanoma | - |
dc.subject.keyword | dabrafenib/trametinib | - |
dc.subject.keyword | first-line treatment | - |
dc.subject.keyword | pembrolizumab | - |
dc.contributor.alternativeName | Chang, Jee Suk | - |
dc.contributor.affiliatedAuthor | 장지석 | - |
dc.contributor.affiliatedAuthor | 김경환 | - |
dc.contributor.affiliatedAuthor | 신상준 | - |
dc.contributor.affiliatedAuthor | 금웅섭 | - |
dc.contributor.affiliatedAuthor | 정기양 | - |
dc.contributor.affiliatedAuthor | 노미령 | - |
dc.contributor.affiliatedAuthor | 김상겸 | - |
dc.citation.volume | 87 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 989 | - |
dc.citation.endPage | 996 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol.87(5) : 989-996, 2022-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.